CeriBell, Inc. (CBLL) has a MoatMap StockRank of 49/100 based on Quality (44/100), Value (37/100), and Momentum (54/100) factor scores. The current signal is HOLD. CeriBell offers innovative point-of-care EEG systems. While the technology is promising and shows good real-world adoption, it is a small-cap medical technology firm that does not align with our 18-month macro themes and lacks the established profitability of a Terry Smith compounder.
CeriBell, Inc. is a medical device company focused on developing non-invasive, rapid neurological assessment tools for the early detection and monitoring of acute neurological conditions such as stroke and concussion. The company's competitive moat lies in its proprietary technology for measuring brain electrical activity, offering the potential for significant clinical impact by enabling timely diagnosis and intervention in critical care and emergency settings. CeriBell represents a high-growth potential player targeting an unmet need in neurological diagnostics.
| Price | $17.18 |
| Market Cap | $708M |
| P/E (Forward) | -17.07 |
| Price/Book | 5.04 |
| Return on Equity | -37.5% |
| Return on Invested Capital | -29.2% |
| Debt/Equity | 15.71 |
| Gross Margin | 87.7% |
| Operating Margin | -78.3% |
| Revenue Growth | 29.3% |
| Free Cash Flow | $-29M |
CeriBell, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).